Stockreport

Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF) [Yahoo! Finance]

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF The study was launched based on RVU120's activity in the RIVER-51 Phase I study in patients with acute myeloid leukemia (AML) and translational data generated in MF. [Read more]